NeuroOne Medical Technologies Corporation Announces Appointment to Scientific Advisory Board
EDEN PRAIRIE, Minn., May 17, 2018 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NMTC), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced the appointment of Dr. Joseph Madsen to the Company’s scientific advisory board.
Dr. Madsen is a pediatric neurosurgeon, Director of Epilepsy Surgery at Children’s Hospital in Boston, Massachusetts and Associate Professor of Harvard Medical School. While pursuing his undergraduate degree at the University of Utah, he worked in the lab of Edwin Catmull, the founder of Pixar. That influence led Dr. Madsen to use his own knowledge of software to implement live 3D models for use in neurosurgery. In addition, Dr. Madsen has authored or co-authored over 300 peer-reviewed papers and currently holds nine patents related to improving care in epilepsy and hydrocephalus.
Dave Rosa, President and CEO of NeuroOne, commented, “We are pleased to have Dr. Madsen working with us. He brings a unique blend of creativity and experience that will be invaluable as we move forward with our thin film electrode technology. Above all, his sincere passion for and commitment to improving patient outcomes in the field of neurosurgery are obvious to those of us that have had the pleasure of meeting him.”
Dr. Madsen joins the following distinguished individuals on NeuroOne’s current scientific advisory board: Dr. Greg Worrell (Mayo Clinic), Dr. Jamie Van Gompel (Mayo Clinic), Dr. Jorge Gonzalez (Cleveland Clinic), Dr. Greg Esper (Emory University), and Justin Williams, Ph.D. (Wisconsin University Research Foundation).
About NeuroOne Medical Technologies Corporation
NeuroOne Medical Technologies Corporation is a medical technology company focused on the development and commercialization of thin film electrode technology for cEEG and sEEG recording, brain stimulation and ablation solutions for patients suffering from Epilepsy, Parkinson’s Disease, Dystonia, Essential Tremors and other related brain related disorders.
Forward Looking Statement
This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this press release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements may include statements regarding the Company’s business strategy, market size, potential growth opportunities, capital requirements, clinical development activities, the timing and results of clinical trials, regulatory submissions, potential regulatory approval and commercialization of the technology. Although the Company believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. These forward‐looking statements are subject to a number of risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the SEC. These forward‐looking statements speak only as of the date of this press release, and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future.
Contact Dave Rosa, CEO NeuroOne Medical Technologies Corporation email@example.com